The history of Viagra presents a nuanced case for stakeholders in the medicinal sector. While initially a tremendous success, generating vast sums, the exclusivity expiration and the subsequent arrival of cheaper alternatives have significantly changed earnings. This presents questions about the long-term sustainability of analogous drug developmen